Corline adds important US and Australian IP within Regenerative Medicine
January 02nd, 2012
Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has been granted approval of Patent Application No. 11/994,457 by the US Intellectual Property Office, and Patent Application No. 2,006,266,501 by Australian Government IP Australia.
“This IP approval is a break-through for Corline in two of the world’s largest and most influential markets for Regenerative Medicine. We know that our technology holds potential to radically improve treatments for patients that in many cases have no options in today’s healthcare. By merit of its broad applicability, the newly granted patents will form a cornerstone in how Corline may build its capabilities and competitive advantage in this fast evolving industry. All to the benefit of patients around the world”, comments CEO Henrik Nittmar.
The patents – both titled ‘Heparin Coating of Biological Tissue’ – cover methods for application and use of the company’s proprietary heparin coating technology for coating all types of biological tissue, such as living cells for transplantation, tissue segments and decellularized tissue matrices.
Corline is developing its technology for use in a multitude of clinical applications in the Regenerative Medicine space, both in partnership with industrial companies from many corners of the world, and together with international research groups in Europe, the US and Australia. A common denominator is that all projects use the same core technology, the one that now has gained improved protection by the newly granted patent applications.
One example of Corline’s internally developed project is that it has developed its unique heparin coating technology for application to Islets of Langerhans, and as such it can attenuate blood mediated inflammation reactions and save valuable donated cells from destruction when transplanted to patients. The Swedish Medical Products Agency has given its approval to start clinical trials for this promising technology.
“We recently received funding from the EU commission, and on the backbone of that we are moving into clinical trials with our core technology in Europe. In parallel we are marketing our technology to several partners in the huge US market, and the newly granted patents are a necessary basis for future investments to realize such a plan. So this is a very good start for Corline in the new year”, concludes CEO Henrik Nittmar.
